Adrian Bogdan Tigu
Overview
Explore the profile of Adrian Bogdan Tigu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
345
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bancos A, Iancu S, Moisoiu V, Ghiaur A, Tigu A, Buran C, et al.
J Cell Mol Med
. 2025 Mar;
29(5):e70244.
PMID: 40042091
Acute promyelocytic leukaemia (APL) is a type of acute myeloid leukaemia characterised by the reciprocal translocation t(15;17), which offers a unique possibility for measurable residual disease (MRD) monitoring by PCR...
2.
Munteanu R, Moldovan C, Tigu A, Drula R, Feder R, Magdo L, et al.
Med Pharm Rep
. 2024 Nov;
97(4):488-506.
PMID: 39502764
Background And Aims: Non-small cell lung cancer (NSCLC) treatment is challenged by late detection and limited therapeutic options. Aberrant DNA methylation, a common epigenetic alteration in NSCLC, offers new therapeutic...
3.
Orzan R, Tigu A, Nechita V, Nistor M, Agoston R, Gonciar D, et al.
J Clin Med
. 2024 Oct;
13(20).
PMID: 39458127
: Cholangiocarcinoma (CCA) is a highly aggressive cancer of the bile ducts with a poor prognosis and limited diagnostic markers. This study aims to investigate the potential of miR-18a and...
4.
Jitaru C, Peters M, Aggarwal L, Bancos A, Tigu A, Cenariu D, et al.
J Cell Mol Med
. 2024 Oct;
28(20):e18592.
PMID: 39435884
No abstract available.
5.
Tigu A, Wiedman G, Szedlacsek S
Front Pharmacol
. 2024 Oct;
15:1494396.
PMID: 39372207
No abstract available.
6.
Tomai R, Iluta S, Tigu A, Nistor M, Bancos A, Cenariu D, et al.
Diagnostics (Basel)
. 2024 Sep;
14(18).
PMID: 39335764
: Spontaneous remission of cancer is a rare and poorly understood phenomenon characterized by complete or partial remission of a malignancy in the absence of or with inadequate treatment. The...
7.
Gulei D, Moisoiu V, Kegyes D, Drula R, Iluta S, Tigu A, et al.
J Cell Mol Med
. 2024 Sep;
28(18):e70078.
PMID: 39334509
Myelodysplastic syndromes (MDS) are myeloid malignancies with heterogeneous genotypes and phenotypes, characterized by ineffective haematopoiesis and a high risk of progression towards acute myeloid leukaemia (AML). Prognosis for patients treated...
8.
Pop V, Iancu M, Tigu A, Adam A, Tomoaia G, Farcas A, et al.
Curr Issues Mol Biol
. 2024 Sep;
46(9):9330-9341.
PMID: 39329904
Multiple myeloma, the disease characterized by the malignant proliferation of plasma cells that invades the bone marrow, produces osteolytic lesions and secretes monoclonal proteins. Several biomarkers have been shown to...
9.
Mihu C, Popescu C, Cenariu D, Vesa S, Baican A, Melincovici C, et al.
J Med Life
. 2024 Jul;
17(3):353-359.
PMID: 39044928
Psoriasis is a chronic skin disease that affects a significant number of patients and can severely impair quality of life. Although the diagnosis is normally clinical, paraclinical determination can occasionally...
10.
Tigu A, Tomuleasa C
Biomedicines
. 2024 Jun;
12(6).
PMID: 38927551
Cancer progression and initiation are sustained by a series of alterations in molecular pathways because of genetic errors, external stimuli and other factors, which lead to an abnormal cellular function...